Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Blood Pressure Medication Recalls

Recalls of ARBs, ACE inhibitors, beta blockers and other hypertension drugs - the class behind the large valsartan and losartan nitrosamine recalls.

549 recalls in this category, newest first.

Class III · Low risk

Metoprolol Tartrate Injection

Failed pH Specifications: Upward shift in the pH of the solution within the shelf life of the impacted lots.

Terminated Failed specification Baxter Healthcare Corporation D-0222-2019
Class I · High risk

Hydrochlorothiazide Tablets USP

Product Mix-Up: customer complaint that a sealed bottle labeled as Hydrochlorothiazide Tablets USP 12.5 mg contained only Spironolactone Tablets USP 25 mg.

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-182-01 D-1206-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1145-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1144-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1143-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1142-2018
Class II · Moderate risk

Amlodipine

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1141-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1136-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1135-2018
Class II · Moderate risk

Valsartan Tablets USP

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-1134-2018
Class II · Moderate risk

Valsartan Tablets USP 320 mg

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Preferred Pharmaceuticals, Inc NDC 68788-6882-9 D-1107-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-786-13 D-1133-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-785-15 D-1132-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-784-15 D-1131-2018
Class II · Moderate risk

Valsartan Tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity AVKARE Inc. NDC 50268-783-15 D-1130-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-363-90 D-1106-2018